Enveric Biosciences Inc reports results for the quarter ended in January - Earnings Summary

Enveric Biosciences

13/08/2024 03:24

* Enveric Biosciences Inc  ENVB.OQ  reported a quarterly
adjusted
loss of 25 cents​​ per share for the quarter ended in January,
higher than the same quarter last year, when the company
reported EPS of $-3.04.  The lone analyst forecast for the
quarter was for a loss of 55 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Enveric Biosciences Inc's reported EPS for the quarter was
a
loss of 25 cents​.
    * Enveric Biosciences Inc shares had fallen by 12.1% this
quarter and lost 57.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 2.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Enveric
Biosciences Inc is $8.32 
This summary was machine generated from LSEG data August 13 at
02:24 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.55          -0.25          Beat
 Mar. 31 2024      -0.77          -0.61          Beat
 Dec. 31 2023      -1.54          -1.47          Beat
 Sep. 30 2023      -2.09          -1.30          Beat